On May 28, Ali Health fell 3.21% in regular trading, trading at HK$3.62/share, with trading volume of HK$132 million, extending post-earnings weakness.

The decline reflects continued selling pressure following the company's FY26 results, which showed second-half revenue growth of only 7.6%, significantly below market expectations of 13.8%. Multiple major banks subsequently downgraded targets: UBS maintained its \"sell\" rating with a target price cut to HK$3.6; Goldman Sachs lowered its target to HK$4.2; CLSA cut its adjusted net profit forecast by 23%; and Bank of America reduced its target from HK$6 to HK$5.1 while cutting FY27-28 adjusted net profit estimates by approximately 20%.

Adding further pressure, newly issued prescription drug online retail guidelines — prohibiting AI-based prescription review substitution and restricting promotional activities for prescription drugs — are expected to raise platform compliance costs and weigh on near-term profitability for pharmaceutical e-commerce players. Sector peers also declined, with JD Health down 3.07% and Ping An Good Doctor down 4.34%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)